| Dr Markus Meyer, MD | |
|
2450 Riverside Ave, Minneapolis, MN 55454-1450 | |
| (612) 672-6000 | |
| Not Available |
| Full Name | Dr Markus Meyer |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 32 Years |
| Location | 2450 Riverside Ave, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003871955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 042-0011122 (Vermont) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 66097 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Minnesota Medical Center, Fairview | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Express Care | 3375645179 | 1523 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | University Of Minnesota Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477598118 PECOS PAC ID: 9830001189 Enrollment ID: O20031104000532 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Healtheast Woodwinds Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356309322 PECOS PAC ID: 9638082563 Enrollment ID: O20031107000110 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Range Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669569265 PECOS PAC ID: 8022920024 Enrollment ID: O20031110000095 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Healtheast St Joseph's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134186273 PECOS PAC ID: 2365348869 Enrollment ID: O20031208000245 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Healtheast St John's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447218482 PECOS PAC ID: 9234035742 Enrollment ID: O20031208000320 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Healtheast Care System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194787465 PECOS PAC ID: 7214833763 Enrollment ID: O20031208000483 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | Fairview Express Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053952606 PECOS PAC ID: 3375645179 Enrollment ID: O20081028000548 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Entity Name | University Of Minnesota Health Clinics And Surgery Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053795187 PECOS PAC ID: 9133423304 Enrollment ID: O20160209000524 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Markus Meyer, MD 400 Stinson Blvd Fl 2, Minneapolis, MN 55413-2614 Ph: () - | Dr Markus Meyer, MD 2450 Riverside Ave, Minneapolis, MN 55454-1450 Ph: (612) 672-6000 |
News Archive
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
With pressure from the tough economy to bring in extra dollars, more people are sacrificing sleep to work night shifts or two jobs in order to make ends meet, says Raman Malhotra, M.D., assistant professor of neurology at Saint Louis University and director of the SLU Sleep Disorders Center.
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
› Verified 2 days ago
Pascal Frino, M.D Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Veterans Dr, Minneapolis, MN 55417 Phone: 612-467-3183 | |
Dr. Ronald Alexander Reilkoff, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Eugenia Shmidt, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 507-284-2511 | |
Daniel Tesfaye Kebed, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2450 Riverside Ave, Minneapolis, MN 55454 Phone: 612-672-6000 Fax: 612-273-4098 | |
Tenzin Yangchen, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2925 Chicago Ave, Minneapolis, MN 55407 Phone: 612-863-4000 Fax: 763-236-3026 | |
Shelley M Lennox, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 920 E 28th St, Suite 700, Minneapolis, MN 55407 Phone: 612-863-9062 Fax: 612-863-9252 |